应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BEAM Beam Therapeutics, Inc.
休市中 11-20 16:00:00 EST
20.90
-0.04
-0.19%
盘后
21.66
+0.76
+3.65%
19:46 EST
最高
22.10
最低
20.54
成交量
388.66万
今开
20.60
昨收
20.94
日振幅
7.45%
总市值
21.59亿
流通市值
19.15亿
总股本
1.03亿
成交额
8,188万
换手率
4.24%
流通股本
9,160万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读|Beam Therapeutics盘中上涨5.21%,镰状细胞病疗法进展持续支撑情绪
行情直击 · 11-20 23:05
异动解读|Beam Therapeutics盘中上涨5.21%,镰状细胞病疗法进展持续支撑情绪
异动解读|Beam Therapeutics盘中上涨5.07%,镰状细胞病疗法进展持续支撑情绪
行情直击 · 11-19 23:15
异动解读|Beam Therapeutics盘中上涨5.07%,镰状细胞病疗法进展持续支撑情绪
异动解读|Beam Therapeutics盘中上涨6.83%,镰状细胞病疗法进展持续发酵
行情直击 · 11-18
异动解读|Beam Therapeutics盘中上涨6.83%,镰状细胞病疗法进展持续发酵
异动解读|Beam Therapeutics盘中下跌9.35%,镰状细胞病疗法利好后股价仍承压
行情直击 · 11-17
异动解读|Beam Therapeutics盘中下跌9.35%,镰状细胞病疗法利好后股价仍承压
Beam Therapeutics在欧洲呼吸学会2026年大会上公布Beam-302治疗α-1抗胰蛋白酶缺乏症1/2期临床试验最新数据
美股速递 · 09-08
Beam Therapeutics在欧洲呼吸学会2026年大会上公布Beam-302治疗α-1抗胰蛋白酶缺乏症1/2期临床试验最新数据
Beam Therapeutics公布2026年第二季度财务业绩,并宣布在α-1抗胰蛋白酶缺乏症(AATD)领域Beam-302试验全球关键队列中首例患者完成给药
美股速递 · 08-04
Beam Therapeutics公布2026年第二季度财务业绩,并宣布在α-1抗胰蛋白酶缺乏症(AATD)领域Beam-302试验全球关键队列中首例患者完成给药
木头姐日内调仓分化 持续加码航天军工 减持农业基因标的
金吾财讯 · 07-16
木头姐日内调仓分化 持续加码航天军工 减持农业基因标的
基因编辑概念普升 安捷伦科技(A)领涨4.21% 机构指美国FDA相关疗法审评新规利好相关标的
金吾财讯 · 06-24
基因编辑概念普升 安捷伦科技(A)领涨4.21% 机构指美国FDA相关疗法审评新规利好相关标的
Beam Therapeutics宣布其用于治疗苯丙酮尿症的在研新药Beam-304获美国FDA临床试验许可
美股速递 · 06-18
Beam Therapeutics宣布其用于治疗苯丙酮尿症的在研新药Beam-304获美国FDA临床试验许可
Beam Therapeutics Inc.盘中异动 大幅下跌5.20%报27.00美元
市场透视 · 2025-03-10
Beam Therapeutics Inc.盘中异动 大幅下跌5.20%报27.00美元
Beam Therapeutics Inc.盘中异动 股价大跌5.09%
市场透视 · 2025-03-06
Beam Therapeutics Inc.盘中异动 股价大跌5.09%
Beam Therapeutics Inc.盘中异动 早盘急速下挫5.18%报23.80美元
市场透视 · 2025-03-04
Beam Therapeutics Inc.盘中异动 早盘急速下挫5.18%报23.80美元
数据:在PEPE、BEAM等代币上损失千万美元的巨鲸转向购买BTC和MKR
金色财经 · 2025-03-04
数据:在PEPE、BEAM等代币上损失千万美元的巨鲸转向购买BTC和MKR
Beam Therapeutics Inc.盘中异动 下午盘股价大跌5.13%报24.99美元
市场透视 · 2025-03-04
Beam Therapeutics Inc.盘中异动 下午盘股价大跌5.13%报24.99美元
某巨鲸以1.17美元均价增持534万枚ONDO,曾投资PEPE及BEAM亏损超1400万美元
金色财经 · 2025-03-03
某巨鲸以1.17美元均价增持534万枚ONDO,曾投资PEPE及BEAM亏损超1400万美元
Beam Therapeutics Inc.2024财年实现净利润-3.77亿美元,同比减少183.46%
市场透视 · 2025-03-01
Beam Therapeutics Inc.2024财年实现净利润-3.77亿美元,同比减少183.46%
Beam Therapeutics Inc.盘中异动 大幅下跌5.06%报28.33美元
市场透视 · 2025-02-27
Beam Therapeutics Inc.盘中异动 大幅下跌5.06%报28.33美元
Beam Therapeutics 2024年第四季度GAAP每股收益$(1.09)好于预期$(1.18),截至第四季度末持有8.507亿美元现金及有价证券,预计运营资金可支撑至2027年
财报速递 · 2025-02-25
Beam Therapeutics 2024年第四季度GAAP每股收益$(1.09)好于预期$(1.18),截至第四季度末持有8.507亿美元现金及有价证券,预计运营资金可支撑至2027年
Beam Therapeutics Inc.盘中异动 股价大跌5.07%
市场透视 · 2025-02-22
Beam Therapeutics Inc.盘中异动 股价大跌5.07%
加载更多
公司概况
公司名称:
Beam Therapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Beam Therapeutics Inc.成立于2017年1月25日,是一家生物技术公司,致力于根据其专有的碱基编辑技术创建一类新型的精密基因药物,其愿景是为患有严重疾病的患者提供终身治疗疾病。
发行价格:
--
{"stockData":{"symbol":"BEAM","market":"US","secType":"STK","nameCN":"Beam Therapeutics, Inc.","latestPrice":20.9,"timestamp":1795208400000,"preClose":20.94,"halted":0,"volume":3886582,"hourTrading":{"tag":"盘后","latestPrice":21.6636,"preClose":20.9,"latestTime":"19:46 EST","volume":492767,"amount":10301936.964,"timestamp":1795222003200,"change":0.7636,"changeRate":0.036536,"amplitude":0.041321},"delay":0,"changeRate":-0.001910219675262784,"floatShares":91603300,"shares":103287665,"eps":-1.043813,"marketStatus":"休市中","change":-0.04,"latestTime":"11-20 16:00:00 EST","open":20.6,"high":22.1,"low":20.54,"amount":81883387.94353199,"amplitude":0.074499,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.043813,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1795424400000},"marketStatusCode":7,"adr":0,"listingDate":1580965200000,"exchange":"NASDAQ","adjPreClose":20.94,"preHourTrading":{"tag":"盘前","latestPrice":20.51,"preClose":20.94,"latestTime":"09:29 EST","volume":9636,"amount":200009.05584000002,"timestamp":1795184999999,"change":-0.43,"changeRate":-0.020535,"amplitude":0.053906},"postHourTrading":{"tag":"盘后","latestPrice":21.6636,"preClose":20.9,"latestTime":"19:46 EST","volume":492767,"amount":10301936.964,"timestamp":1795222003200,"change":0.7636,"changeRate":0.036536,"amplitude":0.041321},"volumeRatio":1.0454670243253767,"impliedVol":0.403,"impliedVolPercentile":0.0239},"requestUrl":"/m/hq/s/BEAM","defaultTab":"news","newsList":[{"id":"1199725750","title":"异动解读|Beam Therapeutics盘中上涨5.21%,镰状细胞病疗法进展持续支撑情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1199725750","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199725750?lang=zh_cn&edition=full","pubTime":"2026-11-20 23:05","pubTimestamp":1795187134,"startTime":"0","endTime":"0","summary":"11月20日,Beam Therapeutics盘中上涨5.21%,报21.715美元/股,成交额1135.02万美元。消息面上,市场继续消化公司镰状细胞病候选疗法risto-cel的积极进展,相关临床里程碑仍是近期股价波动的核心催化。此前披露的BEACON 1/2期试验已达到主要疗效及安全性终点,且全部次要终点达成,公司并计划于年底前向FDA提交BLA。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"镰状细胞疗法进展顺利,Beam盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126443447","title":"异动解读|Beam Therapeutics盘中上涨5.07%,镰状细胞病疗法进展持续支撑情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1126443447","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126443447?lang=zh_cn&edition=full","pubTime":"2026-11-19 23:15","pubTimestamp":1795101306,"startTime":"0","endTime":"0","summary":"11月19日,Beam Therapeutics盘中上涨5.07%,报22.075美元/股,成交额1073.76万美元。消息面上,市场仍在持续消化公司镰状细胞病候选疗法risto-cel的积极进展。此前披露的BEACON 1/2期试验已达到主要疗效及安全性终点,且全部次要终点达成,公司并计划于年底前向FDA提交BLA。尽管公司最近披露季度每股亏损1.28美元,高于市场预期的每股亏损1.15美元,且市场对后续收入预期有所下调,但临床里程碑兑现仍提升了投资者对其碱基编辑平台商业化前景的关注。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"镰状细胞病疗法进展顺利,Beam股价盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170059985","title":"异动解读|Beam Therapeutics盘中上涨6.83%,镰状细胞病疗法进展持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1170059985","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170059985?lang=zh_cn&edition=full","pubTime":"2026-11-18 22:40","pubTimestamp":1795012821,"startTime":"0","endTime":"0","summary":"11月18日,Beam Therapeutics盘中上涨6.83%,报22.185美元/股,成交额388.82万美元。消息面上,公司镰状细胞病候选疗法risto-cel的积极临床进展仍在发酵。此前披露的BEACON 1/2期试验已达到主要疗效及安全性终点,且全部次要终点达成,公司并计划于年底前向FDA提交BLA。尽管公司上次财报显示季度每股亏损1.28美元,高于市场预期的每股亏损1.15美元,但临床里程碑兑现提升了投资者对后续申报与产品化路径的关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Beam Therapeutics盘中上涨,镰状细胞病疗法进展持续发酵","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148430700","title":"异动解读|Beam Therapeutics盘中下跌9.35%,镰状细胞病疗法利好后股价仍承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1148430700","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148430700?lang=zh_cn&edition=full","pubTime":"2026-11-17 04:49","pubTimestamp":1794862156,"startTime":"0","endTime":"0","summary":"11月17日,Beam Therapeutics盘中下跌9.35%,报20.695美元/股,成交额4511.73万美元。近期公司消息面主要围绕镰状细胞病候选疗法risto-cel展开。公司此前披露,BEACON 1/2期试验达到主要疗效及安全性终点,且全部次要终点达成,并计划于年底前向FDA提交BLA。不过,公司更早前公布的三季度每股亏损为1.28美元,高于市场预期的每股亏损1.15美元;在临床里程碑兑现后,市场对商业化节奏、持续亏损与估值消化的博弈仍在延续,股价短线承压。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"镰状细胞疗法利好,股价仍承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133255075","title":"Beam Therapeutics在欧洲呼吸学会2026年大会上公布Beam-302治疗α-1抗胰蛋白酶缺乏症1/2期临床试验最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1133255075","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133255075?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:01","pubTimestamp":1788861674,"startTime":"0","endTime":"0","summary":"Beam Therapeutics于欧洲呼吸学会2026年大会上,公布了Beam-302在α-1抗胰蛋白酶缺乏症治疗领域1/2期临床试验的最新临床数据。在大会现场,Beam Therapeutics的研发团队详细阐述了受试者的生物标志物变化、肺功能指标改善趋势以及药物耐受性情况。公司方面表示,这些更新数据进一步验证了Beam-302的潜在疾病修饰作用,并支持其后续临床开发路径的推进。业内分析人士指出,这一进展不仅关乎Beam药业自身管线价值的重估,也可能对AATD现有标准治疗格局构成远期挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4535","BK4505","BK4139","BK4611","LU1861559042.SGD","BK4556","LU1861558580.USD","BEAM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159265220","title":"Beam Therapeutics公布2026年第二季度财务业绩,并宣布在α-1抗胰蛋白酶缺乏症(AATD)领域Beam-302试验全球关键队列中首例患者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1159265220","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159265220?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:01","pubTimestamp":1785841273,"startTime":"0","endTime":"0","summary":"Beam Therapeutics(纳斯达克股票代码:BEAM)今日披露其2026年第二季度的财务表现,同时对外宣布,其针对α-1抗胰蛋白酶缺乏症(AATD)的研究性疗法Beam-302,已在全球关键性临床试验队列中完成首例患者给药。这一里程碑事件,标志着该候选药物在开发进程中迈出了至关重要的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","LU1861558580.USD","BEAM","BK4535","BK4139","BK4505","BK4585","BK4611","LU1861559042.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651443872","title":"木头姐日内调仓分化 持续加码航天军工 减持农业基因标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2651443872","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651443872?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:57","pubTimestamp":1784195848,"startTime":"0","endTime":"0","summary":"当日资金投入力度最大的标的为太空探索技术公司 ,多只 ARK 系 ETF 合计斥资 1670 万美元,买入 122807 股,对应成交均价约 135.99 美元,机构持续加大航天赛道配置比重。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302638","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBXA","ARKG","CBXJ","KTUP","SPCF","BEAM","KTOS","HWAY","ARKB","SPAL","IDNA","DFII","BTRN","SNK","BFAP","ARKW","BITB","SPCH","VEGI","CBTY","SPCX","ARKX","ARKK","BCCC","FMED","MADE","SHLD","WDNA","BTCL","FTAG","SPCU","LOFF","159041","BTFX","ARKF","QBF","SPCG","161024","TWST","BETH","KROP","HODL","ARKQ","SARK","DE","BITU","GNOM","TXG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645819136","title":"基因编辑概念普升 安捷伦科技(A)领涨4.21% 机构指美国FDA相关疗法审评新规利好相关标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2645819136","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645819136?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:21","pubTimestamp":1782310862,"startTime":"0","endTime":"0","summary":"金吾财讯 | 美股基因编辑概念普升,截至发稿,安捷伦科技 (A) 涨 4.21%,Beam Therapeutics (BEAM) 涨 3.55%,Intellia Therapeutics (NTLA) 涨 2.95%,Editas Medicine (EDIT) 涨 2.17%,福泰制药 (VRTX) 涨 1.28%。消息面上,建银国际新近研究认为,美国FDA近期发布了基因编辑疗法审评新规,允许药企在提供充分科学可比性论证的前提下,引用“先验知识”或既往成熟研究数据以加速研发,此举这标志着基因编辑疗法审评思路的重要转变,直接利好拥有相关技术平台的企业。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301875","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","IE00B19Z9Z06.USD","LU2462157665.USD","IE00BN0W2V16.EUR","LU2229751404.USD","BK4588","VRTX","IE00BZ9MQY76.HKD","BK4611","LU2236285917.USD","LU2413666699.HKD","LU0079474960.USD","LU1674673691.USD","LU0432979614.USD","IE00B894F039.SGD","LABU","BK4567","EDIT","IE00BN0W2W23.USD","LU0234570918.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU2324357040.USD","NTLA","LU2362541273.HKD","SG9999001176.SGD","LU1674673428.USD","LU2041044095.USD","LU0109394709.USD","SGXZ57979304.SGD","LU1035775433.USD","BEAM","LU0058720904.USD","LU1861559042.SGD","BK4121","SG9999013999.USD","LU2092937221.SGD","IE00BJT1NW94.SGD","IE00B19Z3581.USD","IE00BFTCPJ56.SGD","LU1585245621.USD","LU0256863811.USD","BK4533","A","BK4139","LU2089279066.USD","LU0417517546.SGD","LU2362540622.SGD","LU0889565916.HKD","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168068951","title":"Beam Therapeutics宣布其用于治疗苯丙酮尿症的在研新药Beam-304获美国FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1168068951","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168068951?lang=zh_cn&edition=full","pubTime":"2026-06-18 19:02","pubTimestamp":1781780553,"startTime":"0","endTime":"0","summary":"Beam Therapeutics, Inc. 宣布,其用于治疗苯丙酮尿症的在研新药Beam-304,其新药临床试验申请已获得美国食品和药物管理局的许可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BEAM","BK4588","BK4611","BK4139","BK4585","BK4505","LU1861558580.USD","LU1861559042.SGD","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518220291","title":"Beam Therapeutics Inc.盘中异动 大幅下跌5.20%报27.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220291","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518220291?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:03","pubTimestamp":1741615383,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时03分,Beam Therapeutics Inc.股票出现异动,股价急速下跌5.20%。截至发稿,该股报27.00美元/股,成交量237.165万股,换手率2.83%,振幅3.72%。Beam Therapeutics Inc.股票所在的生物技术行业中,整体跌幅为0.08%。Beam Therapeutics Inc.公司简介:Beam Therapeutics Inc 是一家从事基于其碱基编辑技术创造基因药物的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022030396403e21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022030396403e21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BEAM","BK4535","BK4505","BK4588","BK4139","BK4556","LENZ","BK4585","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517200169","title":"Beam Therapeutics Inc.盘中异动 股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517200169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517200169?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:32","pubTimestamp":1741271528,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时32分,Beam Therapeutics Inc.股票出现异动,股价大幅下挫5.09%。Beam Therapeutics Inc.股票所在的生物技术行业中,整体跌幅为0.66%。其相关个股中,Plus Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Exicure, Inc.涨幅较大,Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃,换手率分别为953.51%、104.36%、48.88%,振幅较大的相关个股有Plus Therapeutics, Inc.、Entero Therapeutics Inc.、Astria Therapeutics, Inc.,振幅分别为24.20%、13.05%、11.88%。Beam Therapeutics Inc.公司简介:Beam Therapeutics Inc 是一家从事基于其碱基编辑技术创造基因药物的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223208a2628fde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223208a2628fde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BEAM","BK4139","BK4585","BK4556","BK4505","BK4535","BK4588","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516670089","title":"Beam Therapeutics Inc.盘中异动 早盘急速下挫5.18%报23.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516670089","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516670089?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:52","pubTimestamp":1741099972,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时52分,Beam Therapeutics Inc.股票出现异动,股价大幅跳水5.18%。截至发稿,该股报23.80美元/股,成交量20.2093万股,换手率0.24%,振幅2.47%。Beam Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为0.32%。Beam Therapeutics Inc.公司简介:Beam Therapeutics Inc 是一家从事基于其碱基编辑技术创造基因药物的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304225252abe7f683&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304225252abe7f683&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4505","BK4556","BK4588","BK4585","BEAM","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516619511","title":"数据:在PEPE、BEAM等代币上损失千万美元的巨鲸转向购买BTC和MKR","url":"https://stock-news.laohu8.com/highlight/detail?id=2516619511","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516619511?lang=zh_cn&edition=full","pubTime":"2025-03-04 12:42","pubTimestamp":1741063374,"startTime":"0","endTime":"0","summary":null,"market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"jinse_live","url":"https://x.com/OnchainLens/status/1896779398776512797","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://x.com/OnchainLens/status/1896779398776512797","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["BEAM","ETH.USD.HKCC","XBTmain","BTCmain","BK4505","BTC","MKR.USD.HKCC","BK4556","BK4585","MKR.USD.CC","BTC.USD.HKCC","BK4139","BK4588","ETH","BK4535","BK4601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516663938","title":"Beam Therapeutics Inc.盘中异动 下午盘股价大跌5.13%报24.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516663938","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516663938?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:28","pubTimestamp":1741033681,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时28分,Beam Therapeutics Inc.股票出现波动,股价大幅跳水5.13%。截至发稿,该股报24.99美元/股,成交量81.582万股,换手率0.97%,振幅6.47%。Beam Therapeutics Inc.股票所在的生物技术行业中,整体跌幅为0.03%。Beam Therapeutics Inc.公司简介:Beam Therapeutics Inc 是一家从事基于其碱基编辑技术创造基因药物的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042801abe695f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042801abe695f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4556","BEAM","BK4505","BK4588","BK4535","BK4139","LENZ","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516786035","title":"某巨鲸以1.17美元均价增持534万枚ONDO,曾投资PEPE及BEAM亏损超1400万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516786035","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516786035?lang=zh_cn&edition=full","pubTime":"2025-03-03 10:58","pubTimestamp":1740970730,"startTime":"0","endTime":"0","summary":null,"market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"jinse_live","url":"https://x.com/OnchainLens/status/1896388254917955585","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://x.com/OnchainLens/status/1896388254917955585","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["BEAM","BK4535","BK4505","BK4139","BK4585","BK4556","MKR.USD.HKCC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516341379","title":"Beam Therapeutics Inc.2024财年实现净利润-3.77亿美元,同比减少183.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516341379","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516341379?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:01","pubTimestamp":1740758461,"startTime":"0","endTime":"0","summary":"3月1日,Beam Therapeutics Inc.公布财报,公告显示公司2024财年净利润为-3.77亿美元,同比减少183.46%;其中营业收入为63.52百万美元,同比减少83.20%,每股基本收益为-4.58美元。从资产负债表来看,Beam Therapeutics Inc.总负债3.70亿美元,其中短期债务13.47百万美元,资产负债比为2.99,流动比率为4.83。机构评级:截至2025年3月1日,当前有14家机构对Beam Therapeutics Inc.目标价做出预测,其中目标均价为48.43美元,其中最低目标价为24.00美元,最高目标价为80.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000154a258185b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000154a258185b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BEAM","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514186503","title":"Beam Therapeutics Inc.盘中异动 大幅下跌5.06%报28.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514186503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514186503?lang=zh_cn&edition=full","pubTime":"2025-02-27 01:57","pubTimestamp":1740592630,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日01时57分,Beam Therapeutics Inc.股票出现异动,股价急速下挫5.06%。截至发稿,该股报28.33美元/股,成交量52.8583万股,换手率0.63%,振幅5.50%。Beam Therapeutics Inc.股票所在的生物技术行业中,整体跌幅为0.43%。Beam Therapeutics Inc.公司简介:Beam Therapeutics Inc 是一家从事基于其碱基编辑技术创造基因药物的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270157109893d107&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270157109893d107&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BEAM","BK4505","BK4535","BK4585","LENZ","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166657736","title":"Beam Therapeutics 2024年第四季度GAAP每股收益$(1.09)好于预期$(1.18),截至第四季度末持有8.507亿美元现金及有价证券,预计运营资金可支撑至2027年","url":"https://stock-news.laohu8.com/highlight/detail?id=1166657736","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166657736?lang=zh_cn&edition=full","pubTime":"2025-02-25 20:39","pubTimestamp":1740487180,"startTime":"0","endTime":"0","summary":"Beam Therapeutics报告季度每股亏损$,好于分析师预期的$,超出预期7.63%。相比去年同期盈余的$1.73,这一数字下降了163.01%。以上内容来自Benzinga Earnings专栏,原文如下:Beam $Therapeutics$ reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 7.63 percent. This is a 163.01 percent decrease over earnings of $1.73 per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513899211","title":"Beam Therapeutics Inc.盘中异动 股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513899211","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513899211?lang=zh_cn&edition=full","pubTime":"2025-02-22 03:07","pubTimestamp":1740164828,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日03时07分,Beam Therapeutics Inc.股票出现异动,股价快速下跌5.07%。截至发稿,该股报31.46美元/股,成交量84.827万股,换手率1.02%,振幅7.39%。Beam Therapeutics Inc.股票所在的生物技术行业中,整体涨幅为0.34%。Beam Therapeutics Inc.公司简介:Beam Therapeutics Inc 是一家从事基于其碱基编辑技术创造基因药物的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222030709abd7e75f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222030709abd7e75f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4556","BK4505","BK4535","BEAM","LENZ","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beamtx.com","stockEarnings":[{"period":"1week","weight":-0.0845},{"period":"1month","weight":-0.1586},{"period":"3month","weight":-0.2977},{"period":"6month","weight":-0.2703},{"period":"1year","weight":0.0146},{"period":"ytd","weight":-0.246}],"compareEarnings":[{"period":"1week","weight":-0.0856},{"period":"1month","weight":-0.1077},{"period":"3month","weight":-0.0991},{"period":"6month","weight":-0.0749},{"period":"1year","weight":0.0571},{"period":"ytd","weight":0.0116}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Beam Therapeutics Inc.成立于2017年1月25日,是一家生物技术公司,致力于根据其专有的碱基编辑技术创建一类新型的精密基因药物,其愿景是为患有严重疾病的患者提供终身治疗疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.016429},{"month":2,"riseRate":0.666667,"avgChangeRate":0.107924},{"month":3,"riseRate":0,"avgChangeRate":-0.199132},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.070856},{"month":5,"riseRate":0.571429,"avgChangeRate":0.076367},{"month":6,"riseRate":0.857143,"avgChangeRate":0.13469},{"month":7,"riseRate":0.428571,"avgChangeRate":0.035999},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.007384},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.013206},{"month":10,"riseRate":0.571429,"avgChangeRate":0.035779},{"month":11,"riseRate":0.714286,"avgChangeRate":0.108724},{"month":12,"riseRate":0.5,"avgChangeRate":0.076029}],"exchange":"NASDAQ","name":"Beam Therapeutics, Inc.","nameEN":"Beam Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Beam Therapeutics, Inc.(BEAM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Beam Therapeutics, Inc.(BEAM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Beam Therapeutics, Inc.,BEAM,Beam Therapeutics, Inc.股票,Beam Therapeutics, Inc.股票老虎,Beam Therapeutics, Inc.股票老虎国际,Beam Therapeutics, Inc.行情,Beam Therapeutics, Inc.股票行情,Beam Therapeutics, Inc.股价,Beam Therapeutics, Inc.股市,Beam Therapeutics, Inc.股票价格,Beam Therapeutics, Inc.股票交易,Beam Therapeutics, Inc.股票购买,Beam Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Beam Therapeutics, Inc.(BEAM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Beam Therapeutics, Inc.(BEAM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}